| DC5036 |
LY-411575
Featured
|
LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM. |
|
| DC7459 |
LY500307 |
LY500307 is a potent, selective estrogen receptor β agonist with EC50 of 0.66 nM, 32-fold selectivity against estrogen receptor α. Phase 2. |
|
| DC8378 |
Mavatrep(JNJ-39439335)
Featured
|
Mavatrep is an orally bioavailable TRPV1 antagonist (Ki=6.5 nM), exhibits minimal effect on the enzymatic activity (IC50 > 25 μM) of CYP isoforms 3A4, 1A2, and 2D6. |
|
| DC10013 |
Mirogabalin
Featured
|
Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium-channel complexes in the CNS. |
|
| DC10532 |
Mirogabalin besylate
Featured
|
Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium-channel complexes in the CNS. |
|
| DC9398 |
MK-0974 |
MK-0974(Telcagepant) is a highly potent, selective, and orally bioavailable CGRP receptor antagonist with Ki values of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors respectively; displays >1500-fold lower affinity for the canine and rat receptors |
|
| DC9966 |
MK-1064
Featured
|
MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia. |
|
| DC7646 |
MK3697 |
MK-3697 is a third insomnia drug, currently being developed by Merck. MK-3697 is a potent and selective Orexin receptor antagonist with Ki = 0.95 nM. |
|
| DC9901 |
Verubecestat (MK-8931)
Featured
|
MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase. |
|
| DC9993 |
MK-8998
Featured
|
MK-8998 is a novel bioactive compound for the treament of psychiatric disease. |
|
| DC10455 |
NE-100
Featured
|
NE100 hydrochloride is a potent and selective σ1 receptor antagonist (Ki = 0.86 nM) that displays > 55-fold selectivity over σ2 receptors and > 6000-fold selectivity over D1, |
|
| DC11247 |
Nelonicline
Featured
|
Nelonicline (ABT-126) is a potent, selective α7 nicotinic receptor (nAChR) partial agonist for the treatment of cognitive impairment with schizophrenia.. |
|
| DC11469 |
APD125(Nelotanserin)
Featured
|
Nelotanserin is a potent 5-HT2A inverse agonist, a moderately potent 5-HT2C partial inverse agonist and a weak 5-HT2B inverse agonist, with IC50s of 1.7, 79, 791 nM in IP accumulation assays, respectively. |
|
| DC8583 |
Asenapine Maleate
Featured
|
Novel psychopharmacologic agent. Displays antagonist activity at 5-HT, dopamine, noradrenalin and histamine receptor subtypes (pKi values are 8.60, 8.40, 10.15, 9.75, 10.46, 8.84, 9.60, 9.94, 8.85, 8.90, 8.84, 9.38, 8.95, 8.93, 8.9, 9.49, 8.91, 9.00 and 8 |
|
| DC4237 |
NXY-059 (Cerovive) |
NXY-059 (Cerovive) is an EGFR and HER2 autophosphorylation inhibitor, against purified EGFR and HER2 of 10.2 and 9.8 nM, respectively. |
|
| DC11905 |
Opiranserin
Featured
|
Opiranserin (VVZ-149, VVZ-000149) is a potent, selective, mixed glycine GlyT2 transporter blocker (IC50= 0.86 uM), purine P2X3 receptor antagonist (IC50=0.87 uM) and serotonin 5-HT2A receptor antagonist (IC50=1.3 uM). |
|
| DC10394 |
Org-26576 |
Org 26576 is a AMPA receptor positive allosteric modulator. |
|
| DC11113 |
Padsevonil |
Padsevonil (UCB-0942, UCB0942) is a potential anti-seizure agent that functions as a pre- and post-synaptic inhibitor.. |
|
| DC10292 |
Pagoclone |
Pagoclone is an active (+)-enantiomer of the racemate RP 59037. Pagoclone is a partial GABA(A) receptor agonist used for the treatment of panic and anxiety disorders. |
|
| DC10255 |
Parecoxib |
Parecoxib is a selective COX2 inhibitor. |
|
| DCAPI1503 |
PARECOXIB SODIUM |
PARECOXIB SODIUM |
|
| DC9098 |
Paroxetine HCl
Featured
|
Paroxetine hydrochloride hemihydrate is a antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). |
|
| DC7226 |
Perampanel(E2007）
Featured
|
Perampanel(E2007; ER 155055-90) is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials. |
|
| DC10529 |
PF 05089771
Featured
|
PF 05089771 is a Nav1.7 channel blocker extracted from patent WO/2010/079443 A1, compound example 788, has an IC50 of 8.6 nM. |
|
| DC11367 |
PF-04447943
Featured
|
PF-04447943 is a brain-permeable phosphodiesterase (PDE) inhibitor that is selective for PDE9A (IC50 = 12 nM) over other PDEs (IC50s = >940 nM) in enzymatic assays of second messenger hydrolysis. |
|
| DC9915 |
PF04995274,PF 04995274
Featured
|
PF-04995274 is a 5-HT4 receptor partial agonist. It thought to act centrally as a pro-cognitive agent that being developed for the treatment of Alzheimer's disease (AD). |
|
| DC11937 |
PF 05180999
Featured
|
PF-05180999 (PF 5180999) is a potent, selective, brain-penetrating and orally bioavailable phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 1 nM. |
|
| DC10631 |
PF-06273340 |
PF-06273340 is a highly potent, kinases elective, well-tolerated pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, Trk C, respectively. |
|
| DC7201 |
PF-2545920(MP-10)
Featured
|
PF-2545920 a highly selective and potent PDE10A inhibitor with an IC50 of 0.37 nM. |
|
| DC9465 |
Pitolisant (hydrochloride)
Featured
|
Pitolisant Hcl(BF2.649;Ciproxidine ) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).
|
|
